Theratechnologies Inc T.TH

Annual meeting

[Bucknelly21]

I am prepared to vote... we have 922 followers on st, about 12 regular posters here, poor marketing, and a massive failure to capitalize on all the accomplishments. This in the second largest bull market in history. What good does it do if no one sees anything you are achieving and your not shouting out about it everyday to the market. Bottom line in my opinion is while the board has always taken care of itself come proxy time but being able to take care of shareholders long and short they continue to fail on making adequate changes in the way they market the opportunity. You can say ir or whatever you'd like but the board is responsible for making sure that those changes are made. Just like wino said he hoped wouldn't happen is happening every time there is significant news. The tree fell again and no one heard it.

[qwerty22]

The stock is up 50% in two months. The eposters are mostly strong affirmation of stuff we already knew, they've had a really good preclinical program but it's just preclinical. There are limitations to this type of data. It strikes me people are EXPECTING irrational market behaviour and then blaming the company when it doesn't arrive.  

[scarlet1967]

Irrational market behaviour?? I believe the irrational market behaviour has been all over this company for a long time, as mentioned earlier the SP had no problem to react negatively when there are negative news and now even to positive news. Who is responsible to take care of it if not the company? 50% increase from a multi year depressed level after getting the go a head for NASH phase 3 and

[Bucknelly21]

I'm curious does getting the fda letter to proceed for phase 3 and the market not even sniffing at it the same kind of irrational market behavior you are referring too? 

[scarlet1967]

Many have said it before the valuation is the projection of the market's perception so the market didn't ascribe any value to phase 3 NASH even with FDA's go a head meaning market doesn't believe in their program at all despite the fact that the agency does. Now we know their approach is different which is the possible reason why the market doesn't understand it, they managed

[SPCEO1]

Unless we are missing something the analysts can see, there is just no excuse for the company not being able to convince the market that NASH is real and therefore the stock deserves to be valued like all the other late stage NASH stocks.  I mean, it really should not be hard to convince investors if you have been able to convince the FDA. QWERTY says the FDA will not reverse its decision

[qwerty22]

"QWERTY says the FDA will not reverse its decision on the phase III trial but I have to think that fear of a reversal might be playing a role in this situation." I would never say "will not" when it comes to regulators but...... From what we understand they aren't presenting new data in these continuing discussions so I don't understand how the FDA can reverse their

[SPCEO1]

I don't think they will reverse it but I suggested a fear of reversal is something that may be keeping the market from giving the stock a proper value for that program. And the basis for reversal may be as simple as there is a new sheriff in town at the FDA and he does not like anything the old sheriff did, so he plans to unwind as much of that as he can. Several companies have already been

[jeffm34]

The delay in trial design is most likely related to the differences in approval criteria between the FDA and EMA.  TH is trying to come up with a trial design that will satisfy the FDA and EMA "lack of harmony between the FDA and the EMA complicates the development pathway for NASH:50 While the FDA only requires the achievement of one NASH endpoint (improvement of ≥1 stage in

[SPCEO1]

That is certainly true but the company has also been very clear that there are some issues related to the FDA alone that need to be squared away. The indication is these are not major issues and do not represent something that would jeopardize the trial going forward but that they needed to have some additional tweaks to the trial to make the FDA happy. 

[qwerty22]

That's true for all NASH players but it does not stop most of them being clear on their plans, Akero managed to clearly signal their plan for an unusual 2/3 trial even before the regulators gave their final opinion. I like the idea that it's the difference between the ema and fda that's holding things up but it much more specific to details of the thtx's program than to the general

[qwerty22]

I think you know that I'm most bothered about the confusion around the NASH program, I think we are all concerned about that. I see that confusion as not coming from bad messaging but from the fact the program is ACTUALLY confusing for a number of reasons. A letter to proceed should be a clear solid step forward, it really should follow with the company clarifying how they will proceed. But

[SPCEO1]

My best guess is that the company would not have even said anything about the letter to proceed on the NASH trial if they were not doing the OO. They wanted to put whatever they could out there to get the share price higher before the OO because even they knew it was an OO. But I am sure we would not have heard a thing about the letter to proceed on NASH until they had the final word if they were

[qwerty22]

I agree. I think we both think we'll get that clarification inevitably. The value in the proceed letter hasn't been destroyed just put on hold until clarification.

[jeffm34]

SPCEO1, have to disagree with you there.  That was not a news release to try and increase the share price. The record quarterly sales, NASH phase 3 and start of Oncology had to be made public before the offering could happen.  I think the news release was done in a way to try and keep the share price from running too high above the agreed upon offering price. You can't tell me this

[SPCEO1]

I don't think they even had to mention any of those three things. As you may recall, they got the news on the oncology trial being approved to proceed before Christmas and did not release it immediately, indicating they did not see that as a material item requiring a PR. On NASH, they got the news between Christmas and New Years and did not release that right away either. And on the pre

[jeffm34]

No one could possibly be that bad at their job to put out a news release that way if the intent was to increse the share price

[qwerty22]

I don't believe the growing sales story atm. One very bad Q followed by one good Q averages out at Egrifta sales still well within the long term range and Trogarzo sales growing at a handful of patients per Q. I think there's good reasons to average over those last two Q (weren't the inventory issues???) and for us to still be waiting for evidence of robust growth.

[SPCEO1]

Maybe we will see some evidence of the targeted 20% growth rate being achieveable on Wednesday when they report results. But you are right, we should not be thinking the legacy drug sales are improving like that untl we see actual evidence as the past record on sales has been bad and quite inconsistent. I am hoping the two new sales people have been brought in to build off a positive turn in

[Adonis]

Crazy day.. down -1.5% with all those news.. really crazy.. Why got out the RP saturday why not today or friday when market is open..